Search results for " intravenous"

showing 10 items of 331 documents

Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1.

2009

Purpose. To evaluate the therapeutic effects of L-propionyl-carnitine (LPC) in patients with critical limb ischemia (CLI), as defined by the TASC guidelines. Methods. The study, double-blinded, randomised, assessed intravenous infusion of LPC 1.2 g/day in combination with PGE-1, 60 mg/day (LPC group: 37 patients), or PGE-1 only (control group: 38 patients) in a total of 75 patients suffering from CLI. Treatment duration was 20 days. We evaluated rest pain, maximum walking distance (MWD) and skin ulcer size. Results. In both groups we observed a significant reduction in pain score and ulcer size and an increase in MWD. In the patients treated with the combination, the improvement was greater…

MaleSettore MED/09 - Medicina InternaCardiotonic AgentsVasodilator AgentsProstaglandin E1IschemiaPainWalkinglaw.inventionchemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawIschemiaCarnitinemedicineHumansPharmacology (medical)CarnitineAlprostadilProstaglandin E1Infusions IntravenousAgedPharmacologyLegCritical Limb Ischemiabusiness.industryTherapeutic effectLeg UlcerDrug SynergismGeneral MedicineCritical limb ischemiaL-PropionylcarnitineSkin ulcerMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareTreatment OutcomechemistryAnesthesiaChronic Diseaselipids (amino acids peptides and proteins)Drug Therapy CombinationFemalemedicine.symptomCardiology and Cardiovascular MedicineClaudicationbusinessmedicine.drugCardiovascular drugs and therapy
researchProduct

Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma

2018

Temsirolimus 175 mg once-weekly for 3 weeks, followed by 75 mg once-weekly intravenously dosed (175/75 mg) is approved in the European Union for treatment of relapsed/refractory mantle cell lymphoma (MCL). A phase IV study explored whether similar efficacy, but improved safety could be achieved with 75 mg without 175 mg loading doses (ClinicaTrials.gov: NCT01180049). Patients with relapsed/refractory MCL were randomized to once-weekly temsirolimus 175/75 mg (n = 47) or 75 mg (n = 42). Treatment continued until objective disease progression. Primary endpoint: progression-free survival (PFS). Secondary endpoints included overall survival (OS) and adverse events (AEs). Median PFS was 4.3 versu…

MaleTemsirolimusCancer ResearchLymphomaDrug ResistanceLymphoma Mantle-CellGastroenterology0302 clinical medicineAntineoplastic Combined Chemotherapy Protocols80 and overClinical endpointmedia_commonAged 80 and overHazard ratioHematologyMiddle AgedPrognosisTemsirolimusSurvival RateLocalOncology030220 oncology & carcinogenesisInjections IntravenousRefractory Mantle Cell LymphomaFemaleIntravenousmedicine.drugsafetymedicine.medical_specialtyoverall survivalmantle cell lymphomaAntineoplastic AgentsDrug Administration ScheduleInjections03 medical and health sciencesRefractoryInternal medicinemedicineHumansmedia_common.cataloged_instanceProgression-free survivalEuropean unionAgedSirolimusSalvage Therapybusiness.industryMantle-Cellmedicine.diseaseSurgeryNeoplasm RecurrenceDrug Resistance NeoplasmNeoplasmMantle cell lymphomaNeoplasm Recurrence Localbusinessprogression-free survivalFollow-Up Studies030215 immunology
researchProduct

Changes in myocardial iron content following administration of intravenous iron (Myocardial‐IRON): Study design

2018

Treatment with intravenous ferric carboxymaltose (FCM) has been shown to improve symptoms, functional capacity, and quality of life in patients with heart failure and iron deficiency. However, the underlying mechanisms for these beneficial effects remain undetermined. The aim of this study is to quantify cardiac magnetic resonance changes in myocardial iron content after administration of intravenous FCM in patients with heart failure and iron deficiency and contrast them with parameters of heart failure severity. This is a multicenter, double-blind, randomized study. Fifty patients with stable symptomatic heart failure, left ventricular ejection fraction <50%, and iron deficiency will be r…

MaleTime FactorsMyocardial ironheart failure030204 cardiovascular system & hematologyFerric CompoundsSeverity of Illness IndexVentricular Function Left030218 nuclear medicine & medical imaginglaw.invention0302 clinical medicineiron deficiencyClinical ProtocolsQuality of lifeRandomized controlled triallawCardiac Magnetic Resonance Ferric Carboxymaltose Heart Failure Iron Deficiency Myocardial IronInfusions IntravenousEjection fractionAnemia Iron-DeficiencyGeneral MedicineIron deficiencyferric carboxymaltoseTreatment OutcomeResearch DesignCardiologyFemaleCardiology and Cardiovascular MedicineCardiac function curvemedicine.medical_specialtyTrial DesignsMagnetic Resonance Imaging CinePlacebocardiac magnetic resonance03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansMaltosemyocardial ironAgedHeart Failurebusiness.industryMyocardiumStroke VolumeRecovery of Functionmedicine.diseaseSpainHeart failureHematinicsQuality of Lifebusiness
researchProduct

Photochemically induced, graded cerebral infarction in the mouse by laser irradiation evolution of brain edema

1992

Cerebral infarction was produced in mice by intravenous injection of a photosensitive dye, rose bengal (10 mg/kg), and by focal illumination of the intact skull surface for 3 min with a laser source, operating at 570 nm with power levels of 2, 5, 10, and 20 mW. Location of infarction was made using 2,3,5-triphenyltetrazolium chloride and the time course of edema in the irradiated cerebral hemisphere was evaluated by measuring water, sodium, and potassium content 4, 24, and 72 hr after irradiation. With power levels of 2 and 5 mW, the infarct was restricted to the cortex, whereas with power levels of 10 and 20 mW, it extended to subcortical regions. Increases in water and sodium and decrease…

MaleTime FactorsPhotochemistryPotassiumSodiumInfarctionchemistry.chemical_elementBrain EdemaToxicologyMicechemistry.chemical_compoundCortex (anatomy)EdemaRose bengalAnimalsMedicineIrradiationBrain ChemistryCerebral CortexPharmacologyRose Bengalbusiness.industryCerebral infarctionLasersCerebral InfarctionWater-Electrolyte Balancemedicine.diseaseDisease Models Animalmedicine.anatomical_structurechemistrySpectrophotometryAnesthesiaInjections Intravenousmedicine.symptombusinessBiomedical engineeringJournal of Pharmacological and Toxicological Methods
researchProduct

Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime.

2004

Since oligopeptidic drugs such as beta-lactam antibiotics share the same carriers in humans and animals, the absorption and elimination kinetics of cefuroxime (C) were investigated in rats. Plasma C concentrations were measured by liquid chromatography. Pharmacokinetics and bioavailability of C in the rat were examined after intravenous (i.v.) administration at three doses (1.78, 8.9 and 17.8mg) of cefuroxime sodium and oral administration at two doses (2.02 and 8.9mg) of cefuroxime axetil (CA). Preliminary fits using data from intravenous administration of C showed that the drug disposition kinetics were clearly nonlinear, with an increase in plasma clearance as the intravenous dose increa…

MaleTime FactorsPopulationPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyModels BiologicalIntestinal absorptionPharmacokineticsOral administrationmedicineAnimalsRats WistareducationAntibacterial agenteducation.field_of_studyCefuroximeChemistryBioavailabilityAnti-Bacterial AgentsRatsNonlinear DynamicsInjections IntravenousCefuroxime SodiumCefuroximemedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Synthesis of 3-azabicyclo[3.2.2]nonanes and their antiprotozoal activities.

2015

Several bicyclic compounds, 3-azabicyclo[3.2.2]nonanes, have been prepared. The new compounds were tested for their activities against one strain of the causative organism of Malaria tropica, Plasmodium falciparum K1, which is resistant against chloroquine and pyrimethamine. In addition, their cytotoxicity and their activity against the pathogen of the East African form of sleeping sickness, Trypanosoma brucei rhodesiense, were investigated. Structure-activity relationships are discussed considering data of readily prepared compounds. For the first time, a distinct in vivo activity was observed against Plasmodium berghei in a mouse model. The active compound was further investigated.

MaleTrypanosoma brucei rhodesiensemedicine.drug_classPlasmodium bergheiClinical BiochemistryPlasmodium falciparumAntiprotozoal AgentsPharmaceutical ScienceAdministration OralBiochemistryMiceStructure-Activity RelationshipParasitic Sensitivity TestsChloroquineparasitic diseasesDrug DiscoverymedicineAnimalsPlasmodium bergheiTissue DistributionMolecular BiologyPathogenbiologyBicyclic moleculeDose-Response Relationship DrugMolecular StructureChemistryOrganic ChemistryPlasmodium falciparumTrypanosoma brucei rhodesiensebiology.organism_classificationRatsDisease Models AnimalPyrimethamineTrypanosomiasis AfricanBiochemistryInjections IntravenousAntiprotozoalMolecular MedicineAzabicyclo Compoundsmedicine.drugBioorganicmedicinal chemistry letters
researchProduct

Cerebral haemodynamic changes during propofol-remifentanil or sevoflurane anaesthesia: transcranial Doppler study under bispectral index monitoring

2006

Background. Sevoflurane or propofol–remifentanil-based anaesthetic regimens represent modern techniques for neurosurgical anaesthesia. Nevertheless, there are potential differences related to their activity on the cerebrovascular system. The magnitude of such difference is not completely known. Methods. In total 40 patients, treated for spinal or maxillo-facial disorders, were randomly allocated to either i.v. propofol–remifentanil or inhalational sevoflurane anaesthesia. Transcranial Doppler was used to assess changes in cerebral blood flow velocity, carbon dioxide reactivity, cerebral autoregulation and the bispectral index to assess the depth of anaesthesia. Results. Time-averaged mean f…

MaleUltrasonography Doppler TranscranialHemodynamicsBlood PressurePiperidinesHeart RateMedicineHomeostasisProspective StudiesPropofolUltrasonographyIntraoperativeAdult Anesthetics; Combined; pharmacology Anesthetics; Inhalation; Intravenous; pharmacology Blood Flow Velocity; drug effects Blood Pressure; drug effects Carbon Dioxide; physiology Cerebrovascular Circulation; drug effects Electroencephalography Female Heart Rate; drug effects Homeostasis; drug effects Humans Male Methyl Ethers; pharmacology Middle Aged Monitoring; Intraoperative; methods Piperidines; pharmacology Propofol; pharmacology Prospective Studies Ultrasonography; Doppler; TranscranialCombineddrug effectDopplerElectroencephalographyMiddle AgedAnesthetics CombinedCerebral blood flowInhalationBispectral indexAnesthesiaCerebrovascular CirculationAnesthetics InhalationmethodFemaleIntravenousPropofolAnesthetics IntravenousBlood Flow Velocitymedicine.drugHumanMethyl EthersAdultMonitoringRemifentanilIntravenouTranscranialCerebral autoregulationtranscranial DopplerSevofluranemethodsRemifentanilSevofluranePiperidineMonitoring IntraoperativeHomeostasiHumansAnestheticsbusiness.industryAnestheticCarbon DioxideTranscranial DopplerProspective StudieAnesthesiology and Pain MedicineMethyl Etherdrug effectsphysiologypharmacologybusiness
researchProduct

Effects of anti-cardiolipin antibodies and IVIg on annexin A5 binding to endothelial cells: implications for cardiovascular disease

2010

Anti-phospholipid antibodies (aPL), including anti-cardiolipin antibodies (aCL), are risk factors for cardiovascular disease (CVD) in the general population and in patients with the anti-phospholipid syndrome (APS; Hughes syndrome). APS may be primary but is also common in patients with systemic lupus erythematosus (SLE). The anti-coagulant protein annexin A5 (ANXA5) is implicated in CVD by interfering with phospholipids and aPL.ANXA5 binding to human umbilical venous endothelial cells (HUVECs) was determined by flow cytometry.When cells were cultured in serum from APS patients with a high aPL titre (aPL-S), binding of ANXA5 to HUVECs was reduced. Monoclonal immunoglobulin (Ig)G aPL against…

MaleUmbilical Veinsmedicine.medical_specialtyEndotheliumPopulationImmunologyImmunoglobulin Gchemistry.chemical_compoundRheumatologyReference Valuesimmune system diseasesAntiphospholipid syndromeInternal medicineCardiolipinmedicineHumansImmunology and AllergyAnnexin A5educationneoplasmsCells CulturedProbabilityeducation.field_of_studyBinding Sitesbiologybusiness.industryEndothelial CellsImmunoglobulins IntravenousGeneral MedicineAntiphospholipid SyndromeFlow Cytometrymedicine.diseaseEndocrinologymedicine.anatomical_structurechemistryCardiovascular DiseasesAntibodies AnticardiolipinCase-Control StudiesImmunoglobulin Gbiology.proteinFemaleAnti-cardiolipin antibodiesAntibodyAnnexin A5businessScandinavian Journal of Rheumatology
researchProduct

Local Delivery of Nimodipine by Prolonged-Release Microparticles—Feasibility, Effectiveness and Dose-Finding in Experimental Subarachnoid Hemorrhage

2012

Background and purposeTo investigate the effect of locally applied nimodipine prolonged-release microparticles on angiographic vasospasm and secondary brain injury after experimental subarachnoid hemorrhage (SAH).Methods70 male Wistar rats were categorized into three groups: 1) sham operated animals (control), 2) animals with SAH only (control) and the 3) treatment group. SAH was induced using the double hemorrhage model. The treatment group received different concentrations (20%, 30% or 40%) of nimodipine microparticles. Angiographic vasospasm was assessed 5 days later using digital subtraction angiography (DSA). Histological analysis of frozen sections was performed using H&E-staining as …

MaleVasodilator AgentsGene ExpressionPolylactic Acid-Polyglycolic Acid CopolymerVasospasm IntracranialDrug DistributionMultidisciplinarymedicine.diagnostic_testMicrofilament ProteinsQRBrainIntracranial ArteryVasospasmAnimal ModelsImmunohistochemistryHemorrhagic StrokeNeurologyAnesthesiaInjections IntravenousToxicityMedicinemedicine.symptomMicrotubule-Associated ProteinsResearch Articlemedicine.drugDrugs and DevicesDrug Research and DevelopmentSubarachnoid hemorrhageCerebrovascular DiseasesScienceNeurosurgeryBrain damageDrug Administration ScheduleModel OrganismsmedicineAnimalsPharmacokineticsLactic Acidcardiovascular diseasesRats WistarBiologyNimodipineDose-Response Relationship Drugbusiness.industryCalcium-Binding ProteinsAngiography Digital SubtractionDigital subtraction angiographySubarachnoid Hemorrhagemedicine.diseaseRatsnervous system diseasesDelayed-Action PreparationsAngiographyRatNimodipineSurgerybusinessPolyglycolic AcidPLoS ONE
researchProduct

Assessment of postischemic neurogenesis in rats with cerebral ischemia and propofol anesthesia.

2009

Background Postischemic endogenous neurogenesis can be dose-dependently modulated by volatile anesthetics. The intravenous anesthetic propofol is used during operations with a risk of cerebral ischemia, such as neurosurgery, cardiac surgery, and vascular surgery. The effects of propofol on neurogenesis are unknown and, therefore, the object of this study. Methods Eighty male Sprague-Dawley rats were randomly assigned to treatment groups with propofol administration for 3 h: 36 mg x kg(-1) x h(-1) propofol with or without cerebral ischemia and 72 mg x kg(-1) x h(-1) propofol with or without cerebral ischemia. In addition, 7 rats with propofol administration for 6 h and 14 treatment-naive ra…

Malebusiness.industryDentate gyrusNeurogenesisNeurogenesisIschemiaHippocampusCell Differentiationmedicine.diseaseBarnes mazeBrain IschemiaRatsBrain ischemiaRats Sprague-DawleyAnesthesiology and Pain MedicineAnesthesiaAnestheticmedicineAnesthesia IntravenousAnimalsPropofolbusinessPropofolmedicine.drugAnesthesiology
researchProduct